

1 **Epithelial lacrimal gland tumors in dogs and cats: is the human WHO**
2 **classification appropriate for animals?**

3

4

5

6 Giudice C¹, Nordio L^{1,2}, Cadonici M¹, Perelli N¹, Caniatti M¹.

7

8 ¹Department of Veterinary Medicine, Università degli Studi di Milano, Italy; ² Clinica

9 Privata San Marco, Padova

10

11

12

13

14

15

16

17

18

19

20 Corresponding author:

21 Chiara Giudice

22 Via Dell'Università 6

23 26900 Lodi, Italy

24 chiara.giudice@unimi.it

25

26 **Abstract**

27 Lacrimal gland tumors (LGT) in dogs and cats are rare neoplasms that can affect either
28 the nictitans (NLG) or the main lacrimal gland (MLG). A consistent classification
29 scheme for canine and feline LGTs is lacking, however the importance of a
30 classification scheme for LGTs has been emphasized in the human literature, and an
31 update to the WHO classification has recently been published. The aim of this study
32 was to investigate the occurrence of different subtypes of canine and feline LGTs in
33 accordance with the human WHO classification system. Epithelial LGTs (n=46 tumors;
34 38 dogs, 8 cats) were reviewed and immunophenotyping for p63, CK14, SMA,
35 calponin, CKAE1/AE3 and CK 19 was performed. Consistent with previous literature
36 reports, lacrimal carcinomas outnumbered adenomas in dogs and cats. Based on the
37 WHO classification of human LGTs, the most common subtypes identified in dogs were
38 pleomorphic, ductal, adenoid cystic, and epithelial-myoeithelial carcinoma. In cats, a
39 lower number of subtypes was observed, and adenocarcinoma “Not Otherwise
40 Specified” (NOS) was the most frequent diagnosis. An uncommon case of feline
41 epithelial-myoeithelial carcinoma was also observed. The application of the human
42 WHO - LGT classification scheme to canine and feline tumors increased the diversity
43 of diagnoses and allowed for the identification of numerous subtypes. Further studies
44 to identify possible correlations between pathological subtypes and prognosis are
45 warranted.

46

47 Keywords: nictitans, lacrimal gland, immunohistochemistry, dog, cat, surgical
48 pathology, neoplasia.

49

50

51 LGTs in dogs and cats are rare but well-known tumors which can affect either the
52 NLG or MLG. The MLG is a diamond-shaped structure in the periorbital tissues at the
53 dorsolateral aspect of the globe. The MLG provides most of the tear secretion in both
54 humans and carnivores^{30, 32}. The NLG is an ovoidal gland (about 10 mm) surrounding
55 the ventral portion of the third eyelid cartilage ^{26,29}. No NLG or third eyelid are present
56 in humans, in whom minor/accessory lacrimal glands (Wolfring and Krause glands)
57 located near the superior conjunctival fornix contribute to tear secretion ³². Accessory
58 lacrimal glands are probably also present in dogs and cats, although specific
59 anatomical studies are lacking ^{21, 30}.

60 The MLG and NLG have similar histological features and are affected by the same
61 type of tumors. They are exocrine glands, organized in lobules separated by loose
62 connective tissue that contains interlobular ducts, vessels and nerve fibers. Each
63 lobule is composed of acini and intralobular ducts lined by polygonal epithelial cells.
64 Myoepithelial cells are distributed around the acini and intercalated ducts. MLG and
65 NLG produce seromucous secretion in dogs and predominantly serous secretion in
66 cats and humans ^{15,28,30}.

67 Recently, a new classification has been published for human LGTs¹² and the human
68 literature emphasizes the importance of a detailed classification that distinguishes
69 subtypes of LGTs for both study and prognostic purposes ^{1,2,4,35}. Benign tumors
70 constitute about half of human epithelial LGT tumors and malignant epithelial tumors
71 comprise the other half. Human LGTs are currently classified based mainly on
72 neoplastic cell morphology, reflecting their differentiation to acinar, ductal, or myo-
73 epithelium. Pleomorphic adenoma is the most common LGT in humans, representing
74 20% of all LGTs. It is composed of both epithelial and myoepithelial cells, along with
75 areas of mesenchymal tissue (fibrous, bone, or cartilage). Pleomorphic adenoma is

76 benign but can recur if incompletely excised, and a small number of cases give rise
77 to carcinoma (named carcinoma ex-pleomorphic adenoma). The most common
78 malignant epithelial LGT in humans is adenoid cystic carcinoma, comprising 20–30%
79 of all malignant LGTs. It is composed of both epithelial and myoepithelial cells
80 organized in various patterns of growth (cribriform, tubular, or solid). The
81 histopathological features of adenoid cystic carcinoma have prognostic implications:
82 the solid pattern is associated with a worse prognosis, and perineural invasion is
83 associated with local recurrence, while bone invasion is associated with a fatal
84 outcome. Additional rarer malignant epithelial LGTs include epithelial-myoepithelial
85 and ductal carcinoma^{1,2,4,35}. Epithelial-myoepithelial carcinoma is described as a low-
86 grade malignant tumor histopathologically characterized by a “biphasic arrangement
87 of inner luminal cuboidal cells and outer myoepithelial cells”¹². High grade
88 transformation of epithelial-myoepithelial carcinoma with anaplasia, increased mitotic
89 rate, and loss of distinctive biphasic pattern has been described. Ductal carcinoma of
90 lacrimal glands, similarly to ductal carcinoma of salivary gland, is described in
91 humans as an aggressive epithelial tumor characterized by comedonecrosis and a
92 cribriform growth pattern^{22, 24}. Other rare LGTs are listed in Table 1.

93 A consistent morphological classification of LGTs in dogs and cats is lacking. A few
94 reports have been published describing what have been called “atypical epithelial
95 tumors” or “pleomorphic tumors” of the canine lacrimal glands^{5,16,23, 34}. These tumors
96 were essentially characterized by a myoepithelial or basal phenotype. In the single
97 extensive descriptive study⁶, which reviewed 145 canine and feline LGTs, no
98 information was provided concerning specific histopathological features and/or
99 immunophenotype.

100 The aim of the present study was therefore to describe the morphological features of
101 canine and feline LGTs, applying the new human WHO classification system in order
102 to identify a common and consistent nomenclature for different neoplastic subtypes.
103 For the purposes of this study, the histopathological diagnosis was supported by a
104 immunohistochemical investigation mainly directed toward the identification of
105 myoepithelial cells.

106

107 **Materials and Methods**

108 A retrospective search (2005-2020) through the archive of the Department of
109 Veterinary Medicine (DIMEVET) of the Università degli Studi di Milano was
110 performed. The search criteria included primary epithelial neoplasms arising from the
111 glandular tissue of the NLG or the MLG in dogs and cats, from formalin-fixed,
112 hematoxylin and eosin (HE)-stained 5- μ m paraffin sections of submitted tissues.
113 Surface-neoplasms affecting the NLG (e.g., conjunctival squamous cell carcinoma)
114 were excluded as they were not considered primary glandular neoplasms. Moreover,
115 cases that lacked available material for histopathological review (HE-stained slides or
116 paraffin blocks) were excluded from this study.

117 The collected patient data included species, age, sex, breed, recurrence (confirmed
118 or suspected), and metastatic spread (histologically confirmed or diagnosed with
119 imaging techniques). Veterinary ophthalmologists were contacted via email for
120 patient follow-up information. Recurrence was confirmed when neoplastic tissue was
121 noted clinically at the surgical site and diagnosed via cytology or histology.

122 The tumor size was measured on the HE-stained sections as the two greatest tumor
123 dimensions. Complete longitudinal sections of the specimens were available for all
124 cases.

125 All HE-stained sections of the tumors were reviewed (CG, LN). Surgical margins
126 were defined as complete (tissue margins free of neoplastic cells for a distance of
127 greater than 1 mm), or incomplete (neoplastic cells extended to the cut tissue
128 margin). When the tissue margins free of neoplastic cells were < 1 mm, surgical
129 margins were indicated as "close". Tumors were classified based on the most recent
130 WHO classification of human tumors of the lacrimal gland (Table 1). The main
131 criterion for the definition of malignancy was the presence of an infiltrative (overt or
132 micro-infiltrative) growth pattern. According to the current literature^{6,9,11,12}, micro-
133 infiltrative growth was recorded when a tumor was surrounded by an incomplete thin
134 connective tissue capsule, multifocally infiltrated by neoplastic cells.

135 Mitotic counts were determined in all cases evaluating 10 contiguous HPF (40 ×
136 objective, 10× ocular FN 22 mm). Counts were determined starting in the most
137 proliferative area and avoiding areas with necrosis or severe inflammation.

138 Serial four-micrometer thick sections were obtained from paraffin blocks and stained
139 with Alcian blue pH 2.5 (Diapath staining Kit, BG, Italy) to highlight the presence of
140 mucus-secreting cells and ground substance.

141 For immunohistochemistry, serial 4-micrometers sections were mounted on positively
142 charged glass slides (Superfrost Plus; Thermo Fisher Scientific, Waltham, MA), and
143 dried at 60°C for 20 minutes. The following antigens were analyzed: pan-cytokeratins
144 (CKAE1/3), cytokeratin 19 (CK 19), cytokeratin 14 (CK 14), calponin, alpha-smooth
145 muscle actin (SMA), and p63 (Table 2). Immunohistochemistry was manually
146 performed applying the standard ABC method. Briefly, the sections were dewaxed in
147 xylene and rehydrated through graded alcohols; the endogenous peroxidase activity
148 was blocked with 0.3% H₂O₂ in methanol for 30 min. Blocking was obtained with a 1-

149 hour incubation at RT using normal horse serum. Different antigen retrieval methods
150 were applied (Table 2). The primary antibodies were incubated overnight at 4°C. The
151 immunohistochemical reaction was revealed through an avidin-biotin complex
152 method using biotinylated horse anti-mouse antibody (Vector Laboratories,
153 Burlingame, USA) and an AEC (3-amino-9-ethylcarbazole) substrate-chromogen kit
154 (Vector Laboratories, Burlingame, USA). The sections were counterstained with
155 Mayer's hematoxylin. A portion of the normal lacrimal gland included in the
156 specimens served as the positive internal control for all antibodies, and the negative
157 control consisted of a serial section of each specimen, where primary antibodies
158 were replaced with normal mouse serum (non-immune serum, Dako, Carpinteria,
159 USA).

160 Interpretation of immunohistochemical results was performed by two board-certified
161 veterinary pathologists (CG, LN). For each tumor, the entire section was evaluated
162 and immunolabeling of cells was reported as positive or negative, independent of
163 signal intensity.

164 **Results**

165 Canine LGTs

166 Thirty-eight LGTs from 38 dogs, were retrieved. Case 31 was a local recurrence of
167 case 30) and case 10 was the complete excision of a previously biopsied mass
168 (cases 9) (Supplemental Table 1.).

169 Most tumors arose within the NLG (34/38, 90%) and only 2/38 (5%) affected the
170 MLG. Two cases were diagnosed as lobular orbital adenomas and the precise gland
171 of origin was not determined.

172 Males (19/38, 50%; 4 neutered) and females (17/38, 45%; 8 neutered) were almost
173 equally represented, and in 2 cases the sex was not reported. The age of dogs
174 affected by LGTs varied from 4 to 16 years (mean 10.7; median 7 years). Different
175 breeds were usually represented by a single individual (Supplemental Table S1).
176 Malignant LGTs were diagnosed in 34/38 (90%) cases from 34 dogs, and benign
177 LGTs were diagnosed in 4/38 (10%) cases. Details are provided as Supplemental
178 Table S1.

179 Of the 34 malignant LGTs, the NLG was affected in 32 cases (94%) and the MLG in
180 2 cases. Males and females were almost equally represented (14 females; 18 males;
181 and in 2 cases the sex was not reported). Several breeds were represented and the
182 dogs' age varied from 4 to 16 years (mean 11, median 10.5) (Supplemental Table
183 S1). The surgical margins were considered complete in 20/34 (60%) cases, close in
184 4 cases (11%), and incomplete in 10 cases (29%). Follow-up data were available in
185 only 15 cases (cases 2, 11, 12, 13, 17, 18, 19, 21, 23, 24, 25, 27, 29, 30/31 and 34).
186 Follow-up period varied from 3 to 24 months (mean 10, median 12). Among cases for
187 which follow-up was available, one had close margins (case 21) and four had
188 incomplete margins (cases 17, 24, 30/31); however a local recurrence was reported
189 only in cases 30/31 and metastatic spread was not reported.

190 The most frequent diagnoses were pleomorphic carcinoma and ductal carcinoma
191 (seven cases each), followed by epithelial-myoepithelial carcinoma (6 cases) and
192 adenoid cystic carcinoma (5 cases).

193 *Pleomorphic carcinoma.* Pleomorphic carcinoma is composed of epithelial (malignant)
194 and myoepithelial (benign) neoplastic cells and areas of well-differentiated chondroid,
195 myxoid, fibrous or bone tissue. There is generally a considerable variation in the
196 proportions of these components.

197 In the present series, seven of 34 cases (20%) were diagnosed as pleomorphic
198 carcinoma (cases 1-7 Supplemental Table S1). Tumors were composed of both
199 epithelial/myoepithelial and mesenchymal-like tissues. Epithelial cells were variably
200 arranged in tubules or in solid cords and nests with surrounding myoepithelial cells
201 that trailed out gradually into myxomatous mesenchyme. Mesenchymal tissue was
202 variably represented by areas of hyaline stroma, or islands of bone or chondroid
203 tissue (Figure 1). Foci and areas of necrosis were present in all cases. Mitoses were
204 observed in both epithelial and myoepithelial components. The mitotic count ranged
205 from 3 to 20 mitoses/10 HPF (mean 10). Of the 7 cases, 5 had complete margins,
206 and in 2 cases margins were considered close. In all cases, Alcian blue intensely
207 stained the tumor stroma.

208 Immunohistochemically, the myoepithelial component stained positively with CK14,
209 CALP and SMA, except for one case (case 5) where CALP was negative. P63 was
210 positive in 4 cases and negative in 3/36. Tubular structures were highlighted by
211 positive staining for CKAE1/3 and CK19.

212 *Ductal carcinoma*

213 Ductal carcinoma is an aggressive tumor with differentiation to the interlobular ducts,
214 typically composed of irregularly shaped cystic nodules with central comedonecrosis,
215 lined with carcinoma cells arranged in a cribriform pattern.

216 In the present series, 6/34 tumors (18%) from 6 dogs were diagnosed as ductal
217 carcinomas (cases 8-14). Cases 9 and 10 represented an incisional biopsy and
218 subsequent radical surgery of the same tumor. ductal carcinomas were composed of
219 epithelial cells predominantly arranged in lobules with prominent central necrosis
220 resembling comedonecrosis, and lined by epithelial cells organized either in solid
221 nests or in a cribriform architecture with “Roman bridge” formation. (Figure 2).

222 Neoplastic cells were characterized by high nuclear/cytoplasmic ratio, moderate
223 amount of dark eosinophilic cytoplasm, and oval nuclei with finely stippled chromatin.
224 The mitotic count ranged from 1 to 39 per 10 HPF (mean 21.7). The margins were
225 complete in 4, close in 1 and incomplete in 2 cases. No Alcian positive stroma or
226 secretion was present.

227 In one case (case 9) paraffin-embedded material was insufficient for
228 immunohistochemistry. In all remaining tumors (6/7), epithelial neoplastic cells were
229 consistently positive for CKs. p63 was positive in 4/6 cases, and SMA and CALP
230 were positive in 2/6 cases, where they stained a thin, incomplete rim of myoepithelial
231 cells delineated scattered solid lobules.

232 *Epithelial-myoepithelial carcinoma*

233 Epithelial-myoepithelial carcinoma is composed of two distinct cell populations, i.e.
234 epithelial and myoepithelial. In the present series 6/34 (17%) cases were classified as
235 epithelial-myoepithelial carcinoma (cases 15-20). One case (case 18) was the
236 recurrence of a MLG tumor excised 2 months before with a marginal excision and
237 originally diagnosed as myoepithelioma. The primary tumor was not included in this
238 series due to lack of available material for the review of the case.

239 Epithelial-myoepithelial carcinomas were composed of both epithelial and
240 myoepithelial cells organized either in a distinctive pattern of tubules with inner
241 epithelial and outer myoepithelial cells, or in a more solid pattern with myoepithelial
242 overgrowth (Figure 3). In all cases, both epithelial and myoepithelial cells were
243 considered malignant. Mesenchymal tissue (bone, cartilage, or hyaline stroma)
244 suggestive of pleomorphic carcinoma was never present. The mitotic activity ranged
245 from 0 to 12 mitoses/10 HPF (mean 4.5). Mitoses were observed in both the

246 epithelial and myoepithelial cells. Three epithelial-myoepithelial carcinomas had
247 complete margins and 3/6 incomplete margins.

248 Alcian blue diffusely stained the neoplastic stroma. Immunohistochemistry was
249 performed in 5/6 tumors (in case 20, paraffin-embedded material was insufficient).
250 The epithelial cells stained intensely CK AE1/3 and CK19 positive while the
251 myoepithelial component was intensely and diffusely positive for CK14, p63, CALP
252 and SMA. (Figure 4-6)

253 *Adenoid cystic carcinoma*

254 Adenoid cystic carcinoma are tumors composed of small, uniform cords, and/or solid
255 nests, frequently surrounded by basophilic mucoid or hyaline material. The same
256 material fills small cystic spaces within cellular aggregate. Neoplastic cells have
257 hyperchromatic nuclei and a small amount of indistinct basophilic cytoplasm.
258 Myoepithelial-like cells are also present in stromal regions.

259 In the present series, 5/34 (15%) cases were classified as adenoid cystic carcinoma
260 (cases 21-25). The tumors were characterized by predominant tubular or cribriform
261 growth pattern, with smaller areas of solid growth pattern (Figure 7). Necrosis and
262 perineural growth were not prominent features. The mitotic activity ranged from 3 to
263 19 mitoses/10 HPF (mean 10). Four cases had complete margins and one case
264 incomplete margins (case 24, Table 3. Suppl.).

265 Alcian blue positive stroma was present in 3/5 cases. The neoplastic cells were
266 diffusely positive for all immunohistochemical markers tested (Figures 8-10), with the
267 exception of case 23 that was CALP-negative.

268 *Myoepithelial Carcinoma (MYO)*

269 Myoepithelial carcinomas are tumors composed entirely of myoepithelial cells,
270 proliferating in trabeculae or sheets, sparse residual non-neoplastic ductular
271 structures can occasionally be seen.

272 In the present caseload two tumors (case 26 and 27), were almost completely
273 composed of myoepithelial cells and were diagnosed as myoepithelial carcinomas.
274 Histologically, the tumors were densely cellular, composed of spindle, polygonal, or
275 clear cells organized in trabeculae or sheets with a delicate fibrous stroma.
276 Occasionally, small ducts (interpreted as non-neoplastic residual structures) were
277 encountered. Cells had a moderate amount of faintly eosinophilic cytoplasm and
278 normochromatic, round to oval, smoothly bordered nuclei. The mitotic count was 2
279 and 3 mitoses/10 HPF respectively. Both cases had complete margins.

280 Alcian blue diffusely stained the neoplastic stroma in both cases. In both cases
281 neoplastic cells were diffusely positive for p63, CALP and SMA, and negative for
282 CK14, CK19 and CKAE1/3 (with the exception of occasional scattered ductular
283 structures).

284 In one case (case 28,), an *adenocarcinoma with sebaceous differentiation* was
285 diagnosed. The tumor was mainly composed of cuboidal epithelial cells arranged in
286 tubules or solid sheets. In addition, there were numerous cells morphologically
287 reminiscent of mature sebocytes scattered throughout the mass or organized in small
288 groups. These cells had abundant, finely vacuolized cytoplasm and small central to
289 paracentral, darkly stained nucleus occasionally scalloped by the intracytoplasmic
290 vacuoles. The surgical margins were complete. The Alcian blue stain was negative.
291 The neoplastic cells were diffusely positive for CKAE1/3 and CK19, while CK14
292 intensely labeled sebocyte-like cells. P63, CALP, and SMA were diffusely negative.

293 In one case, (case 29) an *adenocarcinoma with oncocytic features* was diagnosed.
294 The tumor was composed of variably sized tubules lined by two distinct cell
295 populations, one composed of cuboidal to columnar luminal cells, that merged in a
296 second population composed of polygonal cells with poorly defined cell borders, a
297 low N/C ratio, bland nuclei, and abundant intensely eosinophilic granular cytoplasm.
298 This second population was prominent enough to warrant the diagnosis of oncocytic
299 differentiation. The surgical margins were complete. Alcian blue stained negative.
300 Neoplastic cells were positive for p63, CKAE1/3, CK14 and CK19, and negative for
301 CALP and SMA.

302

303 In one dog, a *squamous cell carcinoma* of the NLG was diagnosed (cases 30, 31 ,
304 Figure S2 Suppl.). Histologically, the tumor was composed of distorted cords and
305 solid nests of epithelial cells with prominent squamous differentiation, that diffusely
306 effaced the NLG architecture. Occasional keratin pearl formation and extensive areas
307 of necrosis were present. The mitotic count was 12 mitoses in 10 HPF. The tumor
308 extended to the surgical margins (incomplete margins). The tumor recurred 3 months
309 later (case 31), as multiple, large (2x1 cm) masses infiltrating and distorting the
310 conjunctival substantia propria of the eyelid. Conjunctival surface epithelium and
311 eyelid epidermis were unaffected. Histologically, tumor recurrence was consistent
312 with squamous cell carcinoma with intense fibroplasia. Mitoses were 41/10 HPF.
313 Neoplastic cells extended to the surgical margins (incomplete margins). Alcian blue
314 stained negative. The neoplastic cells were p63, CKAE1/3 and CK14 positive. CK19
315 stained scattered groups of cells in the first specimen and was mostly negative in the
316 recurrence. CALP and SMA were consistently negative.

317 *Unclassified Carcinomas*

318 There were 5 cases of carcinoma that did not clearly match the features of any entity
319 in the recent human WHO lacrimal gland tumor classification scheme (cases 32-36).

320 One case was classified as *lacrimal adenocarcinoma NOS* (not otherwise specified)
321 (case 32). The tumor was an infiltrative neoplasm composed of epithelial cuboidal
322 cells arranged in tubules with a moderate amount of fibrovascular stroma. Neoplastic
323 cells were characterized by relatively distinct cell margins and a moderate amount of
324 pale eosinophilic cytoplasm. Nuclei were oval and normochromic with a single small
325 nucleolus. Anisokaryosis and anisocytosis were moderate, and the mitotic count was
326 0/10 HPF. The tumor extended to the surgical margins (incomplete margins). The
327 Alcian blue staining was negative. The neoplastic cells were CK AE1/3, CK19, CK 14
328 and p63 positive and calponin and SMA negative.

329 Three tumors were histologically characterized by a pattern of growth consistent with
330 *solid carcinoma* (cases 33-35). Histologically, the tumors were composed of
331 epithelial cells arranged in dense solid sheets or cords supported by a moderate
332 amount of fibrovascular stroma. Neoplastic cells were polygonal, with poorly
333 demarcated cell margins and scant, lightly eosinophilic to basophilic cytoplasm.
334 Nuclei were oval and hyperchromatic with coarsely stippled chromatin and a single
335 central prominent nucleolus. Anisokaryosis and anisocytosis were moderate to
336 severe, and mitoses ranged from 10 to 48/10 HPF (mean 34, median 45). Two cases
337 had complete margins, in 1/3 cases the margins were close. Two (2/3) solid
338 carcinomas were investigated immunohistochemically. Neoplastic cells were positive
339 for all markers tested, and Alcian blue stained the neoplastic stroma positive. In case
340 34, the paraffin-embedded material was insufficient to perform
341 immunohistochemistry.

342 The last case (case 36) was an extremely pleomorphic NLG tumor, with features of
343 myoepithelial carcinoma, areas of squamous metaplasia and tubulopapillary growth.
344 The surgical margins were incomplete. Neoplastic cells were variably positive for all
345 markers tested: myoepithelial cells were positive for p63, CK14, SMA and CALP,
346 tubular cells were CKAE1/3 and CK19 positive, and squamous cells were CKAE1/3
347 and CK14 positive. Alcian blue stained the tumor stroma. The tumor did not clearly
348 match the features of any entity in the lacrimal tumor classification and was defined
349 as an unclassified carcinoma.

350 *Canine Benign LGTs*

351 Four of the 38 canine neoplasms (10%) were benign tumors (cases 37-40).
352 Two tumors (cases 37,38) were clinically and macroscopically similar: they clinically
353 presented as space occupying orbital masses with severe conjunctival swelling, and
354 had a typical botryoid appearance, composed of multiple translucent lobules.
355 Histologically, the tumors were composed of fully differentiated glandular secretory
356 cells with abundant, granular pale eosinophilic cytoplasm. No differentiated ducts
357 were seen. Both cases had incomplete margins. According to the current literature
358 these tumors were classified as canine orbital lobular adenomas ¹⁴. These tumors
359 were included in the cohort of LGTs, because in both cases no clinical or diagnostic
360 imaging features suggestive of a zygomatic gland origin (e.g. a dorso-medial
361 displacement of the eye globe or orbital floor discontinuity) were present. Neoplastic
362 cells of lobular adenomas were immunolabeled only with CK19 and CKAE1/AE3,
363 while SMA; CK14, CALP and p63 were negative.
364 One tumor (case 39) was composed of epithelial cells arranged in tubules that
365 occasionally contained an amorphous eosinophilic secretion. The tubules were lined
366 by a single layer of columnar cells with a moderate amount of faintly eosinophilic

367 cytoplasm, and round to oval nuclei with finely stippled chromatin. Anisokaryosis and
368 anisocytosis were minimal and mitotic figures were undetected (simple adenoma).
369 Paraffin-embedded tissue was insufficient to test the immunohistochemical features
370 of this case.

371 The other tumor (case 40) consisted of two distinct cell populations. The first
372 population shared the same features described for the previous case, and the
373 second population was composed of spindle-shaped myoepithelial cells arranged in
374 loose bundles separating tubular structure. Myoepithelial cells had poorly
375 demarcated borders, a moderate amount of eosinophilic cytoplasm and round to
376 fusiform nuclei with finely stippled chromatin. Anisokaryosis and anisocytosis were
377 minimal and mitotic figures were undetected. The tumor was classified as adenoma –
378 complex type and had complete margins. The complex adenoma had strong
379 cytoplasmic labeling of lobular/acinar cells with CK19 and CKAE1/3, while the
380 myoepithelial cells were intensely and diffusely positive for CK14, CALP and SMA
381 and negative for p63, CK19 and CKAE1/3. In all adenoma cases tested, Alcian blue
382 stained the secretory content within tubular lumina. Follow up data were available for
383 1 benign tumor (case 40) in which no recurrence was reported at 12 months after
384 surgery.

385 Feline Lacrimal Gland Tumors

386 Eight epithelial lacrimal gland tumors were retrieved. Details are provided as
387 Supplemental Table S2. Females were overrepresented (6 females, 2 spayed; 2
388 males, 1 neutered). Mean age of cats with NLG/MLG tumors was 12 years (median
389 15, range 6 – 16 years). Most (7/8) were domestic shorthaired cats and one was
390 Siamese.

391 Five tumors affected the nictitans gland and 3 affected the main lacrimal gland . All
392 tumors were malignant and had infiltrative growth. Follow up data were retrieved in
393 only two cases where no recurrence was recorded (cases 1 and 8; Supplemental
394 Table S2) at six months after surgery.

395 The majority of the feline tumors (5/8, cases 1-5 Table 4, Suppl.) were classified as
396 *adenocarcinoma NOS*, simple, tubular (cases 1-3) or tubulopapillary (cases 4-5). The
397 tumors were poorly demarcated, infiltrative masses, composed of neoplastic cells
398 predominantly arranged in tubules with a moderate amount of fibrovascular stroma.
399 The tubules were lined by 1 to 2 layers of cells that had variable morphology, from
400 cuboidal to cylindrical, with relatively distinct cell margins and moderate amount of
401 pale eosinophilic cytoplasm. Nuclei were mainly oval, normochromic with a single
402 small nucleolus. In addition to these features, the tubulopapillary carcinomas had
403 neoplastic cells variably arranged in tubules or papillae extending into the tubular
404 lumina and supported by a fine fibrovascular connective tissue . Anisokaryosis and
405 anisocytosis were generally moderate, and mitoses ranged from 1 to 21/10 HPF
406 (mean 7.6; median 3). Alcian blue sparsely stained the luminal content. The
407 neoplastic cells were CKAE1/3 and CK 19 positive, with scattered CK14 positive
408 cells. P63, CALP and SMA were always negative.

409 Two feline LGTs (cases 6 and 7) were diagnosed as *ductal carcinoma*. The
410 neoplastic cells were organized in large solid lobules, composed of a thick rim of
411 epithelial cells disposed in a sieve-like pattern and surrounding a large central area of
412 coagulative necrosis (comedonecrosis). The neoplastic cells were polygonal, with a
413 moderate amount of homogeneous eosinophilic cytoplasm and oval nuclei with a
414 single small nucleolus. Anisokaryosis and anisocytosis were moderate, and mitoses
415 were 3 and 22/10 HPF. Neoplastic cells were intensely CKAE1/3 and CK 19 positive,

416 while scattered, mainly basally located cells were CK14 and p63 positive. CALP and
417 SMA were negative. No Alcian blue staining was present.

418 One case (case 8;) was diagnosed as *epithelial-myoepithelial carcinoma*. The tumor
419 was composed of both epithelial and myoepithelial cells and retained the typical
420 pattern of a gland with a distinctive outer myoepithelial and an inner epithelial layer.
421 The epithelial cells were intensely CK AE1/3 and CK19 positive while the
422 myoepithelial component was intensely and diffusely p63, CK14, calponin and SMA
423 positive. Alcian blue sparsely stained the luminal content.

424 Normal Lacrimal Gland

425 Portions of the non-neoplastic lacrimal gland were frequently included in the NLG,
426 and more rarely in MLG tumor specimens. Immunohistochemically, acinar and ductal
427 cells were consistently CKAE1/AE3 and CK19 positive while CK14, SMA and
428 calponin consistently and intensely stained myoepithelial cells surrounding the acini
429 and ducts. p63 stained scattered nuclei at the base of the acini and ducts
430 (myoepithelial nuclei) (Supplemental Figures S3-S6)

431 **Discussion**

432 In humans, primary adenocarcinomas of the lacrimal gland have only recently been
433 subclassified, allowing for important advancements in the management of tumors
434 ^{2,33,34}.

435 In the present case-series, the WHO classification of human LGTs¹² was applied to
436 canine and feline LGTs and four main histopathological subtypes of LGTs were
437 described; namely pleomorphic, ductal, adenoid cystic, and epithelial-myoepithelial
438 carcinomas. Additionally, rarer tumors, also reported in humans, including
439 myoepithelial carcinoma, squamous cell carcinoma , sebaceous carcinoma and
440 oncocytoid carcinoma were described.

441 In humans, pleomorphic carcinoma is considered to arise as a malignant
442 transformation of the more common pleomorphic adenoma, as evidenced by the
443 presence of residual tumor areas with benign features, and therefore frequently
444 indicated as pleomorphic carcinoma-ex pleomorphic adenoma ^{2,12,33,35}. No similar
445 areas with benign features were clearly identified in our cases, and we therefore
446 preferred the term of pleomorphic carcinoma. Pleomorphic adenoma has been
447 previously diagnosed in dogs¹⁶, but was not present in this series.

448 Adenoid cystic carcinoma of the human lacrimal gland is described as a malignant
449 neoplasm composed of both epithelial and myoepithelial cells organized in various
450 patterns, including cribriform, tubular, and solid ^{2,12,33,35}. The tumor has a high rate of
451 recurrence and can give rise to widespread metastasis. Important histopathological
452 features associated with a worse prognosis include solid pattern of growth and
453 perineural invasion ^{12,35}. Tumors in dogs of the present series were mostly
454 characterized by a tubular or cribriform growth pattern, and perineural invasion was
455 never observed.

456 Epithelial-myoepithelial carcinomas and ductal carcinomas are considered rare in
457 humans ^{2,12,35}, while in the present series, they outnumbered the adenoid cystic
458 carcinoma cases. The epithelial-myoepithelial carcinomas in this caseload were in
459 many cases consistent with those that are considered high grade epithelial-
460 myoepithelial carcinomas in humans, i.e. tumors that retain a clear distinction
461 between the myoepithelial and epithelial components but had increased mitotic rate
462 and loss of the typical pattern of growth (i.e., absence of tubules with inner epithelial
463 and outer myoepithelial growth). An epithelial-myoepithelial carcinoma was
464 diagnosed in a cat in this series, to the best of authors' knowledge for the first time in
465 this species.

466 Ductal carcinoma is currently classified under adenocarcinomas of the lacrimal gland
467 in the recent WHO classification of LGTs^{12,22,24,31}, and it is characterized by
468 prominent features of comedonecrosis and sieve-like pattern of intraductal growth.
469 The last feature was particularly prominent in feline ductal carcinomas in the present
470 series.

471 In the present caseload, three cases of uncommon tumors were also described, i.e.
472 squamous cell carcinoma, carcinoma with oncocytic features, and carcinoma with
473 sebaceous differentiation. While not included in the WHO list of LGTs, primary
474 squamous cell carcinoma of the lacrimal gland has been described in humans^{10,17}
475 and a single case has also been previously reported in the dogs⁶.

476 Oncocytoma and oncocytic carcinoma are included in the current WHO classification
477 of human LGTs¹², and to the best of the authors' knowledge, they have never been
478 described before in dogs. In the present case (case 29), the tumor was not entirely
479 composed of cells with oncocytic features so a diagnosis of carcinoma with
480 oncocytoid features was preferred.

481 Sebaceous carcinoma is a rare variant of LGT in humans. It is hypothesized that it
482 derives from the sebaceous metaplasia of ductal epithelium or from sebaceous
483 differentiation within a preexisting tumor^{13,18}. Sebaceous LGT has never been
484 described in dogs, while sebaceous mammary carcinomas are known. It is the
485 authors' opinion that the term "sebaceous" in the present case should be considered
486 to be more descriptive than indicative of a differentiation of neoplastic cells towards
487 sebocytes. In fact, lipid-secreting acini similar to those composing the Harder's gland,
488 have been identified in the canine lacrimal gland¹⁵, and in the authors' experience,
489 they can actually be sporadically seen in sections of the normal nictitans gland. The
490 epithelial cells with finely vacuolized cytoplasm observed in the present case could

491 therefore derive from these lipid-secreting acini which are typical of canine NLG,
492 rather than from the metaplasia of ductal epithelium.

493 A few tumor cases in dogs and numerous tumors in cats remained unclassified.
494 Adenocarcinoma NOS was the most frequent diagnosis in the feline cases (5/8).
495 Unclassifiable cases have also been reported in humans ^{27,35}, which is most likely
496 due to the extreme pleomorphism of LGTs. However, it is also possible that the
497 human classification of LGT imperfectly fits canine and feline LGTs, and that a more
498 species-specific classification has to be created.

499 The LGTs were also characterized by immunohistochemistry. In human medicine it is
500 considered important to identify myoepithelial cells in the study of LGTs ^{7,20,25}.
501 However, it has been shown that a subset of cells within the basal layer of lacrimal
502 gland excretory interlobular ducts can also express SMA and it has been
503 hypothesized that some cell lineages retain plasticity after maturation and can trans-
504 differentiate into other cell types upon injury³. In the present study, calponin and SMA
505 gave the most consistent and overlapping results. CK14 and p63 labeled
506 myoepithelial cells but also ductal carcinoma cells. Moreover, p63 was unexpectedly
507 negative in benign canine lesions, while it was expressed in myoepithelial cells of
508 normal LGs. A loss of p63 expression is usually associated with tumor progression,
509 and the only other study²³ currently investigating p63 in canine LGTs did not include
510 any benign tumors. Therefore it can not be determined to date whether our results
511 represent a lack of reactivity toward a specific p63 isoform, or more simply a problem
512 with fixation.

513 In general, immunohistochemistry was useful for highlighting different cell
514 components of the tumors, and it supported the histomorphological subtyping of
515 tumors but was not strictly necessary for identification and diagnosis of tumor

516 subtypes. Similarly, Alcian blue staining highlighted the neoplastic stroma mainly in
517 areas of myoepithelial proliferation.

518 In the current cases, with the exception of squamous cell carcinoma, no canine
519 tumors metastasized or recurred, regardless of their margin status. In the veterinary
520 literature, canine LGTs are generally considered to be at risk of local recurrence but
521 at a low risk of metastasis, especially if radical surgery with removal of the nictitating
522 membrane is performed ^{9,11,36}. Feline LGTs are generally considered to be more
523 aggressive ^{6,8} and metastasis was reported ¹⁹. In our series, follow-up data were
524 retrieved for only 2 feline cases, with no recurrence or metastasis observed.

525 When comparing the biological behavior of LGTs in humans, dogs and cats, one
526 main anatomical difference should be considered: LGTs generally affect the MLG in
527 humans, but more frequently affect the NLG in animals (the NLG is absent in
528 humans).. While the MLG is located in a fossa behind the supero-temporal orbital
529 rim, close to orbital bones, and innervated by a main branch of the trigeminal nerve,
530 the NLG has no strict connection with the surrounding orbital tissue apart from the
531 nictitans membrane itself, and its innervation is poorly studied but not provided by
532 major nerve branches. The main consequences of this anatomical difference is that
533 NLGTs are more easily and completely excised than MLGTs, and perineural growth
534 and bone invasion--both indicators of recurrence and a worse prognosis in the
535 human literature--are rarely observed in canine and feline LGTs. However, the
536 survival data in dogs and cats of this study are limited by the low number of cases
537 with follow up data, the relatively short period of follow-up, and the lack of a complete
538 clinical staging for the identification of metastatic disease or cause of death. Thus,
539 the behavior of different LGT histopathological subtypes in domestic species remains
540 unknown.

541

542 In conclusion, the present study applied the human WHO classification of LGTs to
543 canine and feline lacrimal tumors to identify different histopathological subtypes. This
544 represents a first attempt to use a consistent and reproducible nomenclature for
545 feline and canine LGTs. Immunohistochemistry has been proven useful for studying
546 the cell components of LGTs but currently it is not considered mandatory for making
547 the diagnosis of LGTs according to the WHO human classification.

548

549 **Acknowledgment**

550 The authors want to thank all those people (students, colleagues, PhD students) that
551 in this difficult period of pandemia, with laboratories sometimes inaccessible, delayed
552 product delivery and no technical support for instrumentation did their very best to
553 help, collecting information, taking pictures, providing documents and sometimes
554 even babysitting. A special thanks to Dr. Marco Rondena, Dr. Matteo Gambini, Dr.
555 Valentina Mezzadri, Dr. Laura Barachetti, Dr Chiara Paratici, Dr. Anna Bonfanti, Dr.
556 Cinzia Frizzo, Dr Robert Corvi and Dr. Domenico Multari.

557

558 **Conflict of interest statement**

559 The authors declared no potential conflicts of interest with respect to the research,
560 authorship, and/or publication of this article.

561

562

563 **Funding**

564 The authors received no financial support for the research, authorship, and/or
565 publication of this article.

566

567 **References**

- 568 1. Alkatan HM., Al-Harkan DH, Al-Mutlaq M, Maktabi A, Elkhamary SM. Epithelial
569 lacrimal gland tumors. A comprehensive clinicopathologic review of 26 lesions
570 with radiologic correlation. *Saudi Journal of Ophthalmology*. 2014;28:49–57.
- 571 2. Andreasen S., Esmaeli B., Von Holstein SL., Mikkelsen LH, Rasmussen PK,
572 Heegaard S. An update on tumors of the lacrimal gland. *Asia-Pacific Journal*
573 *of Ophthalmology*. 2017;6:159–172.
- 574 3. Basova L, Parfitt GJ, Richardson A, et al. Origin and Lineage Plasticity of
575 Endogenous Lacrimal Gland Epithelial Stem/Progenitor Cells. *iScience*.
576 2020;23:101230.
- 577 4. Bernardini FP, Devoto MH, Croxatto JO. Epithelial tumors of the lacrimal
578 gland: an update. *Curr Opin Ophthalmol*. 2008;19:409-413.
- 579 5. Bondoc A, Izawa T, Hirata S. et al. Myoepithelioma of the gland of the third
580 eyelid in a dog. *Journal of Comparative Pathology*. 2014;151:186–189.
- 581 6. Dees DD, Schobert CS, Dubielzig RR, Stein TJ. Third eyelid gland neoplasms
582 of dogs and cats: a retrospective histopathologic study of 145 cases. *Vet*
583 *Ophthalmol*. 2016;19:138-143.
- 584 7. Dewar R, Fadare O, Gilmore H, Gown AM. Best practices in diagnostic
585 immunohistochemistry: Myoepithelial markers in breast pathology. *Arch.*
586 *Pathol. Lab. Med*. 2011;135:422–429
- 587 8. Dorbandt DM, Lundberg AP, Roady PJ, Huey JA, Phillips H, Hamor RE.
588 Surgical excision of a feline orbital lacrimal gland adenocarcinoma with
589 adjunctive cryotherapy and carboplatin-impregnated bead implantation. *Vet*
590 *Ophthalmol*. 2018;21:419-425.
- 591 9. Dubielzig RR, Kertring KL, McLellan GJ, Albert DM. Diseases of the eyelids
592 and conjunctiva. In: *Veterinary Ocular Pathology: A Comparative Review*,
593 Elsevier, Philadelphia; 2010

- 594 10. Fenton S, Srinivasan S, Harnett A, Brown I, Roberts F, Kemp E. Primary
595 squamous cell carcinoma of the lacrimal gland. *Eye*. 2003;17:424-425.
- 596 11. Grahn B., Peiffer R., Wilcock B. *Histologic basis of ocular disease in animals*.
597 Wiley-Blackwell; 2019.
- 598 12. Grossniklaus HE, Eberhart CG, Kivelä TT, editors *WHO classification of*
599 *tumours of the eye*. 4th ed. Lyon: IARC, 2018: 148-165.
- 600 13. Harvey PA, Parsons MA, Rennie IG. Primary sebaceous carcinoma of lacrimal
601 gland: a previously unreported primary neoplasm. *Eye*. 1994;8:592-595.
- 602 14. Headrick JF, Bentley E, Dubielzig RR. Canine lobular orbital adenoma: a
603 report of 15 cases with distinctive features. *Veterinary Ophthalmology*
604 2004;7:47–51.
- 605 15. Hendrix DVH. *Diseases and Surgery of the Canine Conjunctiva and Nictitating*
606 *Membrane*. In: Gelatt KN, ed. *Veterinary Ophthalmology*. 5th ed. John Wiley &
607 Sons, Inc. 2013: 961
- 608 16. Hirayama K, Kagawa Y, Tsuzuki K, et al. A pleomorphic adenoma of the
609 lacrimal gland in a dog. *Vet Pathol*. 2000;37:353-356.
- 610 17. Hotta K, Arisawa T, Mito H, Narita M. Primary squamous cell carcinoma of the
611 lacrimal gland. *Clin Exp Ophthalmol*. 2005;33:534-536.
- 612 18. Kiratli H, Tarlan B, Fırat P. Primary sebaceous carcinoma of the lacrimal
613 gland. *Orbit*. 2012;31:352-354.
- 614 19. Komaromy AM, Ramsey DT, Render JA et al. Primary adenocarcinoma of the
615 gland of the nictitating membrane in a cat. *Journal of the American Animal*
616 *Hospital Association* 1997;33:333–336.
- 617 20. Makarenkova HP, Dartt DA. Myoepithelial cells: their origin and function in
618 lacrimal gland morphogenesis, homeostasis, and repair. *Curr. Mol. Biol.*
619 *Reports*, 2015;1:115–123

- 620 21. McLaughlin SA, Brightman AH 2nd, Helper LC, Primm ND, Brown MG,
621 Greeley S. Effect of removal of lacrimal and third eyelid glands on Schirmer
622 tear test results in cats. *J Am Vet Med Assoc.* 1988;193:820-822.
- 623 22. Milman T, Shields JA, Husson M, Marr BP, Shields CL, Eagle RC Jr. Primary
624 ductal adenocarcinoma of the lacrimal gland. *Ophthalmology.* 2005;112:2048-
625 2051.
- 626 23. Miyazaki A, Yonemaru K, Hirata A, Yanai T, Sakai H. Histopathological and
627 immunohistochemical features of atypical epithelial tumours of the gland of the
628 third eyelid in seven dogs. *Journal of Comparative Pathology,* 2015;152:299–
629 303.
- 630 24. Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T. Salivary duct
631 carcinoma: Updates in histology, cytology, molecular biology, and treatment.
632 *Cancer Cytopathol.* 2020;128:693-703.
- 633 25. Nazeer J, Prakash V, Mandal S, Prakash A. Myoepithelial cells: Structure,
634 function and role in tumor formation. *Int J Dent Health Sci.* 2014;1:155–60.
- 635 26. Nesma I El-naseery, Eman I El-behery, Hanaa M. El-Ghazali, Enas El-Hady.
636 The structural characterization of the lacrimal gland in the adult dog (*Canis*
637 *familiaris*). *Benha Veterinary Medical Journal,* 2016;31:106-116.
- 638 27. Ni C, Kuo PK, Dryja TP. Histopathological classification of 272 primary
639 epithelial tumors of the lacrimal gland. *Chin Med J* 1992;105:481-485.
- 640 28. Obata H. Histopathology of the Lacrimal Gland Cornea 2006;25,Supp.1,82-89.
- 641 29. Park S.A., Taylor K.T., Zwingenberger A.L., et al. Gross anatomy and
642 morphometric evaluation of the canine lacrimal and third eyelid glands.
643 *Veterinary Ophthalmology* 2016;19:230-236.

- 644 30. Samuelson, DA; Ophthalmic Anatomy. In: Gelatt, KN, Gilger, BC and Kern,
645 T.J. Ed. *Veterinary Ophthalmology, 5th ed. John Wiley & Sons, Inc.* 2013: 58-
646 60.
- 647 31. See TRO, Stålhammar G, Tang T, et al. Primary ductal adenocarcinoma of the
648 lacrimal gland: A review and report of five cases. *Surv Ophthalmol.*
649 2020;65:371-380.
- 650 32. Takahashi Y, Watanabe A, Matsuda H, et al. Anatomy of secretory glands in
651 the eyelid and conjunctiva: a photographic review. *Ophthalmic Plast Reconstr*
652 *Surg.* 2013;29: 215-219..
- 653 33. von Holstein SL, Coupland SE, Briscoe D, Le Tourneau C, Heegaard S.
654 Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical
655 and oncological survey. *Acta Ophthalmol.* 2013;91:195-206.
- 656 34. Wang FI, Ting CT, Liu YS. Orbital adenocarcinoma of lacrimal gland origin in a
657 dog. *Journal of Veterinary Diagnostic Investigation.* 2001;13:159–161.
- 658 35. Weis E, Rootman J, Joly TJ et al. Epithelial lacrimal gland tumors: Pathologic
659 classification and current understanding. *Archives of Ophthalmology.*
660 2009;127:1016–1028.
- 661 36. Wilcock B, Peiffer R Jr. Adenocarcinoma of the gland of the third eyelid in
662 seven dogs. *J Am Vet Med Assoc.* 1988;193:1549-1550.

663

664 **Figure legends**

665 Figures 1-6. Figure 1. Pleomorphic carcinoma, nictitans lacrimal gland, dog, case 7.
666 Solid epithelial growth and bone tissue. Hematoxylin and eosin (HE). Figure 2. Ductal
667 carcinoma, nictitans lacrimal gland, dog, case 10. Neoplastic cells are organized in a

668 sieve-like pattern of intraductal growth with prominent central necrosis. HE. Figure 3-
669 6. Epithelial-myoepithelial carcinoma, main lacrimal gland, dog, case 18. Figure 3:
670 Area of the tumor characterized by overgrowth of myoepithelial cells. HE. Figure 4.
671 Myoepithelial neoplastic cells around tubular structures have diffuse and intense
672 immunoreactivity for alpha smooth muscle actin (SMA). Figure 5: Neoplastic
673 epithelial cells arranged in tubules have diffuse and intense immunoreactivity for
674 cytokeratin 19. Figure 6: Large groups of myoepithelial cells have diffuse and intense
675 immunoreactivity for cytokeratin 14.

676 Figures 7–10. Adenoid cystic carcinoma, nictitans lacrimal gland, dog, case 6. Figure
677 7. Epithelial cells are arranged in a tubular pattern. Hematoxylin eosin (HE). Figure 8.
678 Mucinous material stains light blue with Alcian blue pH 2.5. Figure 9. Neoplastic cells
679 have diffuse and intense immunoreactivity for cytokeratin 14. Figure 10: Neoplastic
680 cells have diffuse nuclear immunoreactivity for p63.

681 Figures S1-S6 supplemental.

682 Figure S1: a large, round, firm mass protruded from the superotemporal aspect of the
683 left orbit, displacing the eye ventromedially. Severe conjunctival chemosis and
684 hyperemia are present (case 18, Courtesy of Dr. Domenico Multari). Figure S2: cut
685 section of eye globe and nictitans membrane: a large, irregular, poorly demarcated
686 neoplastic mass infiltrates and extensively effaces the nictitans membrane
687 architecture (case 30 Table 3 Suppl). Figures S3-S6 immunohistochemical staining
688 of normal lacrimal gland. Figure S3: myoepithelial cells are intensely stained with
689 alpha smooth muscle actin. Figure S4: myoepithelial cells are intensely stained with
690 calponin. Figure S5 myoepithelial cells are intensely stained with cytokeratin 14.
691 Figure S6: scattered nuclei of myoepithelial cells are stained with p63.

692 Table 1. WHO classification of human lacrimal gland epithelial tumors¹²

693

Adenoid cystic carcinoma
Mucoepidermoid carcinoma
Adenosquamous carcinoma
Carcinosarcoma
Adenocarcinoma of the lacrimal gland
Carcinoma ex pleomorphic adenoma
Pleomorphic adenoma
Myoepithelioma
Myoepithelial carcinoma
Oncocytoma
Oncocytic carcinoma
Epithelial–myoepithelial carcinoma
Low-grade intraductal carcinoma
Secretory carcinoma
Hybrid neoplasms
Acinic cell carcinoma
Adenolymphoma/Warthin tumour

694

695

Table 2 Methods used for immunohistochemistry.

MARKER	CLONE AND BRAND	DILUTION	ANTIGEN RETRIEVAL METHOD	EXPECTED IMMUNOLABELING
p63	mouse, Clone 4A4, Santa Cruz Biotechnology	1:100	HIER	MEC§
CKA1/AE3	Mouse, AE1/AE3, Novus Biologicals	1:2000	PED	EC
CK19	Mouse, NCL-CK19, clone b170, Novocastra	1:200	PED	EC
CK-14	Mouse, Clone LL002, Neomarker	1:2000	HIER	MEC **
CALPONIN	Mouse, clone hCP Sigma Aldrich	1:1000	PED	MEC
Alpha Smooth Muscle Actin (SMA)	Mouse, Clone 1A4 Dakocymation	1:2000	None	MEC***

MEC: myoepithelial cells; EC: epithelial cells; ** CK 14 also stains basal layer of stratifying squamous and non-squamous epithelia

*** SMA also stains myofibroblasts and smooth muscle cells. § also reported in a subpopulation of acinar cells²⁰

HIER: heat-induced epitope retrieval; microwave oven for 10' at 567 W in citrate buffer pH 6.0. PED: pepsin enzymatic digestion (Digest-All Invitrogen; Thermo Fisher Scientific, Carlsbad, USA) 15' at 37°C"